Spots Global Cancer Trial Database for Assess the Oral Bioavailability of New ABT-263 Formulations
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Assess the Oral Bioavailability of New ABT-263 Formulations
Official Title: A Single Dose Study Evaluating the Oral Bioavailability and Pharmacokinetics of the Capsule Formulation of ABT-263 in Subjects With Cancer
Study ID: NCT00743028
Study Description
Brief Summary: This is a randomized, open-label, multicenter crossover study to determine the oral bioavailability of new ABT-263 formulations relative to that of the current ABT-263 formulation being administered in ongoing Phase 1/2a studies. Approximately 36 evaluable subjects with lymphoid malignancies, including chronic lymphocytic leukemia, and solid tumors will be enrolled in this study.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Site Reference ID/Investigator# 10281, Encinitas, California, United States
Site Reference ID/Investigator# 10282, Santa Monica, California, United States
Site Reference ID/Investigator# 16341, Bethesda, Maryland, United States
Site Reference ID/Investigator# 9441, Lebanon, New Hampshire, United States
Site Reference ID/Investigator# 20041, Hackensack, New Jersey, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
